AVITA Medical Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名166/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價6.90。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
AVITA Medical Inc評分
相關信息
行業排名
166 / 404
全市場排名
293 / 4578
所屬行業
生物技術與醫療研究
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
6
分析師
買入
評級
6.900
目標均價
+100.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議
AVITA Medical Inc亮點
亮點風險
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
公司代碼RCEL
公司AVITA Medical Inc
CEOVance (Cary G)
網址https://www.avitamedical.com/
常見問題
AVITA Medical Inc(RCEL)的當前股價是多少?
AVITA Medical Inc(RCEL)的當前股價是 3.440。
AVITA Medical Inc 的股票代碼是什麼?
AVITA Medical Inc的股票代碼是RCEL。
AVITA Medical Inc股票的52週最高點是多少?
AVITA Medical Inc股票的52週最高點是14.160。
AVITA Medical Inc股票的52週最低點是多少?
AVITA Medical Inc股票的52週最低點是3.250。
AVITA Medical Inc的市值是多少?
AVITA Medical Inc的市值是524.48M。
AVITA Medical Inc的淨利潤是多少?
AVITA Medical Inc的淨利潤為-61.84M。
現在AVITA Medical Inc(RCEL)的股票是買入、持有還是賣出?
根據分析師評級,AVITA Medical Inc(RCEL)的總體評級為買入,目標價格為6.900。